MarketResearchNest.com adds “Premenstrual Syndrome – Pipeline Review, H2 2017” new report to its research database. The report spread across in 28 pages with table and figures in it.
Latest Pharmaceutical and Healthcare disease pipeline guide Premenstrual Syndrome – Pipeline Review, H2 2017, provides an overview of the Premenstrual Syndrome (Women’s Health) pipeline landscape.
Premenstrual syndrome (PMS) is a collection of physical and emotional symptoms related to a woman’s menstrual cycle. Premenstrual syndrome has a wide variety of symptoms, including mood swings, tender breasts, food cravings, fatigue, irritability and depression.
Enquiry for buying at: https://www.marketresearchnest.com/enquirybuy.php?reportid=268807
The Premenstrual Syndrome (Women’s Health) pipeline guide also reviews of key players involved in therapeutic development for Premenstrual Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 2, 2 and 1 respectively.
Premenstrual Syndrome (Women’s Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Companies mentioned in this report includes:
Asarina Pharma AB, Pherin Pharmaceuticals Inc
Order a Premium Purchase Report Copy at: https://www.marketresearchnest.com/purchase.php?reportid=268807
Featured News & Press Releases:
Apr 03, 2017: Asarina Pharma Phase IIa clinical study with Sepranolone in premenstrual dysphoric disorder meets primary endpoint.
Sep 19, 2014: Umecrine Mood announces positive results from an exploratory Phase I/II study with UC1010 in premenstrual dysphoric disorder (PMDD)
Jun 12, 2014: Umecrine Mood reports preliminary data from exploratory Phase II study in premenstrual dysphoric disorder
Dec 16, 2013: Patient recruitment completed in the Phase I/II study of Umecrine Mood’s candidate drug for severe premenstrual symptoms
May 23, 2013: Umecrine Mood Announces Dosing Of First Patient In Phase I/II Study Of UC1010 For Premenstrual Dysphoric Disorder
Reasons to buy:
– Procure strategically important competitor information, analysis, and insights to formulate effective RandD strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Premenstrual Syndrome (Women’s Health).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Premenstrual Syndrome (Women’s Health) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Enquiry for Discount at: https://www.marketresearchnest.com/requestdiscount.php?reportid=268807
MarketResearchNest.com is the most comprehensive collection of market research products and services on the Web. We offer reports from almost all top publishers and update our collection on daily basis to provide you with instant online access to the world’s most complete and recent database of expert insights on global industries, organizations, products, and trends.
Mr. Jeet Jain